Straits Times Index
3,314.14 +8.12 (+0.25%) S&P 500
5,461.89 -2.73 (-0.05%) Dow
39,262.40 +112.07 (+0.29%) Nasdaq
17,634.51 -54.85 (-0.31%) Bitcoin USD
61,380.98 -2,900.18 (-4.51%) CMC Crypto 200
1,261.80 -47.91 (-3.66%)
APLS Jan 2025 120.000 put
| Previous close | 64.00 |
| Open | 64.00 |
| Bid | 76.50 |
| Ask | 79.40 |
| Strike | 120.00 |
| Expiry date | 2025-01-17 |
| Day's range | 64.00 - 64.00 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Simply Wall St.Investors might be losing patience for Apellis Pharmaceuticals' (NASDAQ:APLS) increasing losses, as stock sheds 6.3% over the past week
While Apellis Pharmaceuticals, Inc. ( NASDAQ:APLS ) shareholders are probably generally happy, the stock hasn't had...
ZacksApellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.
GlobeNewswireSYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
SYFOVRE is the only approved GA treatment to demonstrate a visual function benefit in a prespecified endpointData presented at the Clinical Trials at the Summit Meeting WALTHAM, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that SYFOVRE® (pegcetacoplan injection) preserved visual function at 36 months in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). These positive data from the GALE long-term ext
